Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Endocrine-Related Cancer

• Publication date

  2004-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1677/ERC.1.00699PMID 15369449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutations in the Androgen Receptor Gene Are Associated with Progression of Human Prostate Cancer to Androgen Independence I

  2008cited by this paper
• Molecular pathology of prostate cancer

  2005cited by this paper
• Is DD3 a new prostate-specific gene?

  2003cited by this paper
• Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population.

  2003cited by this paper
• Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.

  2003cited by this paper
• The growth inhibitory effect of p21 adenovirus on androgen‐dependent and ‐independent human prostate cancer cells

  2003cited by this paper
• New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene.

  2003cited by this paper
• Mitogen‐activated protein kinase pathway is involved in androgen‐independent PSA gene expression in LNCaP cells

  2003cited by this paper
• Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer.

  2003cited by this paper
• DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer

  2003cited by this paper
• Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer

  2003cited by this paper
• Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells.

  2003cited by this paper
• DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

  2003cited by this paper
• Bcl-2 and Bcl-xL differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24

  2003influential reference
• Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.

  2003cited by this paper
• The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity.

  2003cited by this paper
• alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.

  2002cited by this paper
• The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.

  2002influential reference
• Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.

  2002cited by this paper
• Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.

  2002cited by this paper
• Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response.

  2002cited by this paper
• The polycomb group protein EZH2 is involved in progression of prostate cancer

  2002influential reference
• Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease.

  2002influential reference
• Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways*

  2002influential reference
• Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer.

  2002cited by this paper
• The Association of p 21 ( WAF-1 / CIP 1 ) with Progression to Androgen-independent Prostate Cancer 1

  2002cited by this paper
• Her2 expression in prostatic cancer: a comparison with mammary carcinoma.

  2002cited by this paper
• High expression of the Met receptor in prostate cancer metastasis to bone.

  2002influential reference
• α-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation

  2002cited by this paper
• Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer.

  2002cited by this paper
• DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.

  2002cited by this paper
• The development of androgen-independent prostate cancer

  2001cited by this paper
• Delineation of prognostic biomarkers in prostate cancer

  2001influential reference
• Cancer burden in the year 2000. The global picture.

  2001cited by this paper
• Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer.

  2001cited by this paper
• Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate.

  2001cited by this paper
• Amplification of the androgen receptor may not explain the development of androgen‐independent prostate cancer

  2001cited by this paper
• Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.

  2001cited by this paper
• Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer.

  2001cited by this paper
• The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage.

  2001cited by this paper
• DNA-based detection of prostate cancer in urine after prostatic massage.

  2001cited by this paper
• Androgen receptor mutations in prostate cancer.

  2000cited by this paper
• Prognostic Significance of p 53 Nuclear Accumulation in Localized Prostate Cancer Treated with Radical Prostatectomy 1

  2000cited by this paper
• Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.

  2000cited by this paper
• PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.

  2000cited by this paper
• PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer.

  2000cited by this paper
• Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer.

  2000cited by this paper
• Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

  2000cited by this paper
• Identification of differentially expressed genes in human prostate cancer using subtraction and microarray.

  2000cited by this paper
• Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.

  1999influential reference
• DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

  1999cited by this paper
• Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

  1999cited by this paper
• Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations.

  1999cited by this paper
• Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

  1999cited by this paper
• CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk

  1999cited by this paper
• Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression

  1999influential reference
• Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.

  1999cited by this paper
• Androgen receptor gene mutations in hormone‐refractory prostate cancer

  1999cited by this paper
• Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways*

  1999cited by this paper
• (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French–German population

  1999cited by this paper
• From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.

  1999cited by this paper
• A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

  1999cited by this paper
• Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

  1999influential reference
• Activation of mitogen-activated protein kinase associated with prostate cancer progression.

  1999cited by this paper
• Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

  1998cited by this paper
• Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.

  1998cited by this paper
• Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation.

  1998cited by this paper
• Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors

  1998cited by this paper
• Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.

  1997cited by this paper
• Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.

  1997cited by this paper
• Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk.

  1997cited by this paper
• Differentially expressed genes in androgen-dependent and -independent prostate carcinomas.

  1997cited by this paper
• Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor.

  1997influential reference
• Prostate-specific membrane antigen expression in normal and malignant human tissues.

  1997cited by this paper
• A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.

  1997cited by this paper
• Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.

  1997cited by this paper
• The genetic analysis of prostate carcinoma.

  1997cited by this paper
• Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.

  1996cited by this paper
• Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display.

  1995cited by this paper
• In vivo amplification of the androgen receptor gene and progression of human prostate cancer

  1995cited by this paper
• Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function.

  1995cited by this paper
• KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.

  1995cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor.

  1995influential reference
• c-met proto-oncogene expression in benign and malignant human prostate tissues.

  1995cited by this paper
• Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

  1995cited by this paper
• Results of conservative management of clinically localized prostate cancer.

  1994cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

  1994cited by this paper
• Results of conservative management of clinically localized prostate cancer.

  1994cited by this paper
• Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas.

  1992cited by this paper
• Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

  1992cited by this paper
• Androgen receptors in endocrine‐therapy‐resistant human prostate cancer

  1991cited by this paper
• Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas.

  1991cited by this paper
• Activated ras alleles in human carcinoma of the prostate are rare.

  1991cited by this paper
• A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.

  1990cited by this paper
• ras gene mutations in human prostate cancer.

  1990cited by this paper
• Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia.

  1986cited by this paper

• Demethyltransferase FTO alpha-ketoglutarate dependent dioxygenase (FTO) regulates the proliferation, migration, invasion and tumor growth of prostate cancer by modulating the expression of melanocortin 4 receptor (MC4R)

  2021cites this paper
• Association of CYP1A1, GSTM1 and GSTT1 gene polymorphisms with risk of prostate cancer in Algerian population

  2020cites this paper
• Demethylation of miR‐195 suppresses prostate cancer cell proliferation, migration and invasion

  2020cites this paper
• Snail promotes prostate cancer migration by facilitating SPOP ubiquitination and degradation.

  2020cites this paper
• Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression

  2019cites this paper
• IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway

  2019cites this paper
• URG11 Regulates Prostate Cancer Cell Proliferation, Migration, and Invasion

  2018cites this paper
• Correlation between MR spectroscopy and histology in detection of prostatic carcinoma.

  2018cites this paper
• Genetic Polymorphism of GSTM1 and GSTT1 and Risk of Prostatic Carcinoma - a Meta-analysis of 7,281 Prostate Cancer Cases and 9,082 Healthy Controls.

  2016cites this paper
• Praćenje procesa malignih modifikacija stanica prostate i jetara

  2014cites this paper
• ASAP1 mediates the invasive phenotype of human laryngeal squamous cell carcinoma to affect survival prognosis.

  2014cites this paper
• Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro

  2014cites this paper
• Developing New Small Molecular Drugs for Prostate Cancer Therapy

  2013cites this paper
• Androgen-Dependent Oncogenic Activation of ETS Transcription Factors by Recurrent Gene Fusions in Prostate Cancer: Biological and Clinical Implications

  2013cites this paper
• Self-Contained Enzymatic Microassay Biochip for Cancer Detection

  2012cites this paper
• Expression of SHB in prostate cancer tissue: its role in the diagnostics and prognostics

  2012cites this paper
• Genetic Polymorphisms of GSTM1, GSTT1, and GSTP1 with Prostate Cancer Risk: A Meta-Analysis of 57 Studies

  2012cites this paper
• Are GSTM1, GSTT1 and CAG Repeat Length of Androgen Receptor Gene Polymorphisms Associated with Risk of Prostate Cancer in Iranian Patients?

  2011cites this paper
• Statistical Applications in Genetics and Molecular Biology Selection of Biologically Relevant Genes with a Wrapper Stochastic Algorithm

  2011cites this paper
• Recurrence‐free survival in prostate cancer is related to increased stromal TRAIL expression

  2011cites this paper
• P53 Expression in Prostatic Cancer: An Immunohistochemical Study

  2011cites this paper
• Hedgehog signaling protein expression and its association with prognostic parameters in prostate cancer: A retrospective study from the view point of new 2010 anatomic stage/prognostic groups

  2011cites this paper
• XAF 1 expression and regulatory effects of somatostatin on XAF 1 in prostate cancer cells

  2010cites this paper
• XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells

  2010cites this paper
• The relationship between CAG repeat length polymorphism and infertility in Southern Chinese Han women

  2010cites this paper
• The relationship between CAG repeat length polymorphism and infertility in Southern Chinese Han women.

  2010cites this paper
• Issues with the Use of Prostate-Specific Antigen as a Surrogate End Point in Hormone-Resistant Prostate Cancer

  2009cites this paper
• Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer

  2009cites this paper
• Gene Profiling Analysis of Androgen Receptor Mediated Function

  2008cites this paper
• The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer.

  2008cites this paper
• ASAP1, a gene at 8q24, is associated with prostate cancer metastasis.

  2008cites this paper
• Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.

  2007cites this paper
• time-dependent responses in

  2007cites this paper
• Statistical Applications in Genetics and Molecular Biology

  2007cites this paper
• Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-κB in human prostate cell lines: Differential time-dependent responses in cancer progression

  2007cites this paper
• Transcriptomes of human prostate cells

  2006cites this paper
• Application of Genomic Technologies to Human Prostate Cancer

  2006cites this paper
• Prognostic factors in prostate cancer

  2006cites this paper
• Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system.

  2006influential citation
• Operational criteria for selecting a cDNA microarray data normalization algorithm.

  2006cites this paper
• Interplay between two hormone-independent activation domains in the androgen receptor.

  2006cites this paper
• Award Number: W81XWH-04-1-0214 TITLE: Inhibition of Androgen-Independent Growth of Prostate Cancer by siRNA- Mediated Androgen Receptor Gene Silencing

  2006cites this paper
• Oncogenes and Tumor Suppressor Genes in Therapeutic Resistance

  2006cites this paper
• Marqueurs biologiques du cancer de la prostate : Présent et futurs

  2005cites this paper